151 related articles for article (PubMed ID: 31840170)
1. In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18.
Appalaraju B; Baveja S; Baliga S; Shenoy S; Bhardwaj R; Kongre V; Dattatraya GS; Dhole T; Verma B; Mukherjee DN; Gupta S; Shanmugam P; Iravane J; Mishra SR; Barman P; Chopra S; Hariharan M; Surpam R; Pratap R; Joshi P; Khande H; Mane A; Jain R; Bhagwat S
J Antimicrob Chemother; 2020 Mar; 75(3):600-608. PubMed ID: 31840170
[TBL] [Abstract][Full Text] [Related]
2. Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital.
Bakthavatchalam YD; Shankar A; Muniyasamy R; Peter JV; Marcus Z; Triplicane Dwarakanathan H; Gunasekaran K; Iyadurai R; Veeraraghavan B
J Antimicrob Chemother; 2020 Aug; 75(8):2156-2159. PubMed ID: 32361727
[TBL] [Abstract][Full Text] [Related]
3. Assessment of antibacterial activity of levonadifloxacin against contemporary gram-positive clinical isolates collected from various Indian hospitals using disk-diffusion assay.
Baliga S; Mamtora DK; Gupta V; Shanmugam P; Biswas S; Mukherjee DN; Shenoy S
Indian J Med Microbiol; 2020; 38(3 & 4):307-312. PubMed ID: 33154240
[TBL] [Abstract][Full Text] [Related]
4.
Bajpai V; Tiwari S; Mishra A; Sure R; Sarode R; Bharti S; Pandey H; Kapoor A
Microb Drug Resist; 2024 Apr; 30(4):147-152. PubMed ID: 38350157
[No Abstract] [Full Text] [Related]
5. Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.
Bhagwat SS; Nandanwar M; Kansagara A; Patel A; Takalkar S; Chavan R; Periasamy H; Yeole R; Deshpande PK; Bhavsar S; Bhatia A; Ahdal J; Jain R; Patel M
Drug Des Devel Ther; 2019; 13():4351-4365. PubMed ID: 31920285
[TBL] [Abstract][Full Text] [Related]
6. In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital.
Mamtora D; Saseedharan S; Rampal R; Joshi P; Bhalekar P; Ahdal J; Jain R
J Lab Physicians; 2020 Dec; 12(3):230-232. PubMed ID: 33268943
[No Abstract] [Full Text] [Related]
7. Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study.
Bhatia A; Mastim M; Shah M; Gutte R; Joshi P; Kumbhar D; Periasamy H; Palwe SR; Chavan R; Bhagwat S; Patel M; Llorens L; Friedland HD
J Assoc Physicians India; 2020 Aug; 68(8):30-36. PubMed ID: 32738837
[TBL] [Abstract][Full Text] [Related]
8. In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms.
Tellis M; Joseph J; Khande H; Bhagwat S; Patel M
J Med Microbiol; 2019 Aug; 68(8):1129-1136. PubMed ID: 31241446
[TBL] [Abstract][Full Text] [Related]
9. Levonadifloxacin (WCK 771) exerts potent intracellular activity against
Dubois J; Dubois M
J Med Microbiol; 2019 Dec; 68(12):1716-1722. PubMed ID: 31689174
[No Abstract] [Full Text] [Related]
10. India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care.
Veeraraghavan B; Bakthavatchalam YD; Manesh A; Lal B; Swaminathan S; Ansari A; Subbareddy K; Rangappa P; Choudhuri AH; Nagvekar V; Mehta Y; Appalaraju B; Baveja S; Baliga S; Shenoy S; Bhardwaj R; Kongre V; Dattatraya GS; Verma B; Mukherjee DN; Gupta S; Shanmugam P; Iravane J; Mishra SR; Barman P; Chopra S; Hariharan M; Surpam R; Pratap R; Turbadkar D; Taklikar S;
Indian J Med Microbiol; 2023; 41():71-80. PubMed ID: 36509611
[TBL] [Abstract][Full Text] [Related]
11. Levonadifloxacin arginine salt to treat acute bacterial skin and skin structure infection due to S. aureus including MRSA.
Saxena D; Kaul G; Dasgupta A; Chopra S
Drugs Today (Barc); 2020 Sep; 56(9):583-598. PubMed ID: 33025952
[TBL] [Abstract][Full Text] [Related]
12. Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral).
Saseedharan S; Dubey D; Singh RK; Zirpe K; Choudhuri AH; Mukherjee DN; Gupta N; Sahasrabudhe S; Soni S; Kulkarni S; Walse P; Vora AC; Thomas J; Tayade A; Bhadarke G; Kishore K; Paliwal Y; Patil P; Reddy PK; Nagvekar V; Veeraraghavan B
Indian J Med Microbiol; 2024; 47():100528. PubMed ID: 38228227
[TBL] [Abstract][Full Text] [Related]
13. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
[TBL] [Abstract][Full Text] [Related]
14. A comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant
Bakthavatchalam YD; Rao SV; Isaac B; Manesh A; Nambi S; Swaminathan S; Nagvekar V; Nangia V; John PV; Veeraraghavan B
Indian J Med Microbiol; 2019; 37(4):478-487. PubMed ID: 32436868
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
Huband MD; Pfaller MA; Shortridge D; Flamm RK
J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
18. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
Huband MD; Castanheira M; Farrell DJ; Flamm RK; Jones RN; Sader HS; Mendes RE
Int J Antimicrob Agents; 2016 Jun; 47(6):495-9. PubMed ID: 27211209
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
